Health-related quality of life changes among users of depot medroxyprogesterone acetate for contraception
Wanyonyi, S.Z.; Stones, W.R.; Sequeira, E.
Contraception 84(5): E17-E22
2011
ISSN/ISBN: 1879-0518 PMID: 22018133 DOI: 10.1016/j.contraception.2011.05.022Document Number: 223825
Depot medroxyprogesterone acetate (DMPA) may have other noncontraceptive effects that could impact on the quality of life. The objective of this study was to assess the health-related quality of life changes associated with the use of DMPA for contraception. A prospective, observational study using the Short Form-36 quality of life questionnaire. After 6 months of use, the participants had an improved physical summary score, mean change [5.64 (95% confidence interval [CI], 1.87-9.4), p=.054]. There was no significant change in sexual function [5.33 (95% CI, -2.15 to 12.81), p=.0858] and mental summary score [-0.51 (95% CI, -1.90 to 2.92), p=.432]. The main side effect of DMPA was menstrual irregularity (32.5%); 17.2% of the participants found amenorrhea desirable. Besides its contraceptive efficacy, DMPA is associated with an improvement in perceived physical health with no apparent adverse effect on mental health and sexual function.
Document emailed within 0-6 h
